Exact Mass: 664.4020241999999
Exact Mass Matches: 664.4020241999999
Found 71 metabolites which its exact mass value is equals to given mass value 664.4020241999999,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
3-O-trans-Feruloyleuscaphic acid
3-O-trans-Feruloyleuscaphic acid is found in fruits. 3-O-trans-Feruloyleuscaphic acid is a constituent of Eriobotrya japonica (loquat) Constituent of Eriobotrya japonica (loquat). 3-O-trans-Feruloyleuscaphic acid is found in fruits.
PA(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
PA(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of myristoleic acid at the C-1 position and one chain of eicosapentaenoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z))
PA(20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z)), in particular, consists of one chain of eicosapentaenoic acid at the C-1 position and one chain of myristoleic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(10:0/PGF1alpha)
C33H61O11P (664.3951285999999)
PA(10:0/PGF1alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/PGF1alpha), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of Prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGF1alpha/10:0)
C33H61O11P (664.3951285999999)
PA(PGF1alpha/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGF1alpha/10:0), in particular, consists of one chain of one Prostaglandin F1alpha at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
(+)-2alpha,16beta,31-triacetyl-9,11-dihydrobuxiran
C39H56N2O7 (664.4087306000001)
PA(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
PA(20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z))
PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/12:0)
PA(12:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
3-O-trans-Feruloyleuscaphic acid
OON-PG
C33H61O11P (664.3951285999999)
1,11-dihydroxy-10-[(E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
myristoyl-D-asparaginyl-butan-2-aminyl-malonyl-1-aminocyclopropane-1-carboxyl-acetyl-glycine
[(2R)-2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-phosphonooxypropyl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
[1-phosphonooxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
[1-[(Z)-hexadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropyl] (9Z,12Z)-octadeca-9,12-dienoate
[1-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
(1-dodecanoyloxy-3-phosphonooxypropan-2-yl) (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
[1-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-phosphonooxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
[(2R)-1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate
[(2R)-2-dodecanoyloxy-3-phosphonooxypropyl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate
[(2R)-3-phosphonooxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate
[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (10E,12E)-octadeca-10,12-dienoate
[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (E)-octadec-11-enoate
[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (11E,13E,15E)-octadeca-11,13,15-trienoate
[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate
2-[[3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[3-[(6E,9E)-dodeca-6,9-dienoyl]oxy-2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
[(2R)-1-dodecanoyloxy-3-phosphonooxypropan-2-yl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate
10,11-dihydroxy-9-({[3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy}methyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylic acid
n-[(1r,5r,6r,7s,8r,11r,12s,14r,15s,16r)-5,14-bis(acetyloxy)-7-[(acetyloxy)methyl]-15-[(1s)-1-(dimethylamino)ethyl]-7,12,16-trimethyltetracyclo[9.7.0.0³,⁸.0¹²,¹⁶]octadec-3-en-6-yl]benzenecarboximidic acid
C39H56N2O7 (664.4087306000001)
(5r)-3-[(1e)-2-[(1r,4as,5r,6r,8ar)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]ethenyl]-5-[(1s)-2-[(1r,4as,5r,6r,8as)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-(2-oxo-5h-furan-3-yl)ethyl]-5h-furan-2-one
(5s)-3-[(1e)-2-[(1r,4as,5r,6r,8ar)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]ethenyl]-5-{2-[(1r,4as,5r,6r,8as)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-(2-oxo-5h-furan-3-yl)ethyl}-5h-furan-2-one
n-(5-{[3-({4-[(2-amino-5-carbamimidamido-1-hydroxypentylidene)amino]butyl}amino)-1-hydroxypropylidene]amino}pentyl)-2-{[2-(2,4-dihydroxyphenyl)-1-hydroxyethylidene]amino}butanediimidic acid
C30H52N10O7 (664.4020241999999)
n-[5,14-bis(acetyloxy)-7-[(acetyloxy)methyl]-15-[1-(dimethylamino)ethyl]-7,12,16-trimethyltetracyclo[9.7.0.0³,⁸.0¹²,¹⁶]octadec-3-en-6-yl]benzenecarboximidic acid
C39H56N2O7 (664.4087306000001)
(1s,2r,4as,6as,6br,8ar,9s,10s,11r,12ar,12br,14bs)-10,11-dihydroxy-9-({[(2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy}methyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylic acid
5-{2-[6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-(2-oxo-5h-furan-3-yl)ethyl}-3-{2-[6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]ethenyl}-5h-furan-2-one
5-[6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-1-[2-(2-oxo-5h-furan-3-yl)ethyl]-hexahydronaphthalen-1-yl]-3-[(1e)-2-[6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]ethenyl]-5h-furan-2-one
(5s)-5-[(1s)-2-[(1s,4ar,5s,6r,8as)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-(4-oxo-5h-furan-3-yl)ethyl]-3-[(1e)-2-[(1s,4as,5r,6r,8as)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]ethenyl]-5h-furan-2-one
(2s)-n-[5-({3-[(4-{[(2s)-2-amino-5-carbamimidamido-1-hydroxypentylidene]amino}butyl)amino]-1-hydroxypropylidene}amino)pentyl]-2-{[2-(2,4-dihydroxyphenyl)-1-hydroxyethylidene]amino}butanediimidic acid
C30H52N10O7 (664.4020241999999)